New keytruda copycat tested in melanoma trial

NCT ID NCT06551064

Ongoing Disease control Sponsor: Formycon AG Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether FYB206, a biosimilar (or copycat) of the cancer drug Keytruda, works similarly in the body. It involves 96 people with stage IIB/IIC or III melanoma that was completely removed by surgery. Participants receive either FYB206 or Keytruda, and researchers compare how the drug levels behave over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FYB206 (a biosimilar to pembrolizumab/Keytruda)
What this could lead to: If successful, FYB206 could offer a more affordable alternative to Keytruda for preventing melanoma recurrence after surgery.
What could go wrong: This is an early phase 1 trial focused on drug levels in the body, not yet on effectiveness. Biosimilars may not perform identically, and results may not guarantee long-term benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA, STAGE IIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA STAGE II MELANOMA STAGE III

Contacts and locations

Locations

Formycon Investigative Site

Sarajevo, Bosnia and Herzegovina
Formycon Investigative Site

Sofia, Bulgaria
Formycon Investigative Site

Tartu, Estonia
Formycon Investigative Site

Batumi, Georgia
Formycon Investigative Site

Kutaisi, Georgia
Formycon Investigative Site

Tbilisi, Georgia
Formycon Investigative Site

Kaunas, Lithuania
Formycon Investigative Site

Chisinau, Moldova
Formycon Investigative Site

Skopje, North Macedonia
Formycon Investigative Site

Krakow, Poland
Formycon Investigative Site

Lodz, Poland
Formycon Investigative Site

Bucharest, Romania
Formycon Investigative Site

Cluj-Napoca, Romania
Formycon Investigative Site

Belgrade, Serbia
Formycon Investigative Site

Kragujevac, Serbia
Formycon Investigative Site

Niš, Serbia
Formycon Investigative Site

Kyiv, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.